113 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
-LOOKING STATEMENTS
This prospectus contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this prospectus … -looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this press release, including
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than
8-K
EX-99.1
59ej8
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
8-K
xji6i6 6cdgs
15 Mar 24
Other Events
7:15am
424B3
dih17bl 69vww
2 Feb 24
Prospectus supplement
12:00am
8-K
EX-99.1
1hgqcy
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
8b4fl
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:19pm
8-K
EX-99.1
71x0mpatv5 8c40i5nd
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
8-K
EX-99.2
hvkczz7m 3gqidpttqm
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.4
6eiq8 xv3sd9m77a25t
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-99.1
si4vgx dz8
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
epidxnpd
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
4opx pprz3rsv4k62
2 Nov 23
Prospectus supplement with pricing info
9:00am